Lindsay Robert S, Mackin Sharon T, Nelson Scott M
Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, University Place, Glasgow, G12 8TA, UK.
School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK.
BMC Med. 2017 Aug 28;15(1):163. doi: 10.1186/s12916-017-0925-2.
Personalised treatment that is uniquely tailored to an individual's phenotype has become a key goal of clinical and pharmaceutical development across many, particularly chronic, diseases. For type 2 diabetes, the importance of the underlying clinical heterogeneity of the condition is emphasised and a range of treatments are now available, with personalised approaches being developed. While a close connection between risk factors for type 2 diabetes and gestational diabetes has long been acknowledged, stratification of screening, treatment and obstetric intervention remains in its infancy.
Although there have been major advances in our understanding of glucose tolerance in pregnancy and of the benefits of treatment of gestational diabetes, we argue that far more vigorous approaches are needed to enable development of companion diagnostics, and to ensure the efficacious and safe use of novel therapeutic agents and strategies to improve outcomes in this common condition.
针对个体表型量身定制的个性化治疗已成为许多疾病（尤其是慢性病）临床和药物研发的关键目标。对于2型糖尿病，该疾病潜在临床异质性的重要性已得到强调，目前已有一系列治疗方法，且个性化治疗方法也在不断发展。虽然2型糖尿病的危险因素与妊娠期糖尿病之间的密切联系早已得到认可，但筛查、治疗和产科干预的分层仍处于起步阶段。
尽管我们对妊娠期糖耐量以及妊娠期糖尿病治疗益处的理解取得了重大进展，但我们认为需要采取更积极有力的方法来推动伴随诊断的发展，并确保新型治疗药物和策略的有效安全使用，以改善这种常见病症的治疗效果。
